CNR1 and type 1 diabetes mellitus: The yin-yang relationship of CB1R and CB2R actions in islets illustrates the potential therapeutic of Δ9-tetrahydrocannabivarin (THCV), a dual antagonist/agonist for CB1R and CB2R respectively, for treating T1DM that may improve pancreatic β-cell function (Abioye et al., 2020), possibly by promoting autophagy through antagonism of CB1R within β-cells and agonism of CB2R in APC cells (Jadoon et al., 2016).